{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T02:30:13Z","timestamp":1791772213858,"version":"4.3.4"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T00:00:00Z","timestamp":1683763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100003042","name":"Else Kr\u00f6ner-Fresenius-Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003042","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Ataxia due to an autosomal dominant intronic GAA repeat expansion in FGF14 [GAA-FGF14 ataxia, spinocerebellar ataxia 27B (SCA27B)] has recently been identified as one of the most common genetic late-onset ataxias. We here aimed to characterize its phenotypic profile, natural history progression, and 4-aminopyridine (4-AP) treatment response.<\/jats:p>\n               <jats:p>We conducted a multi-modal cohort study of 50 GAA-FGF14 patients, comprising in-depth phenotyping, cross-sectional and longitudinal progression data (up to 7 years), MRI findings, serum neurofilament light (sNfL) levels, neuropathology, and 4-AP treatment response data, including a series of n-of-1 treatment studies.<\/jats:p>\n               <jats:p>GAA-FGF14 ataxia consistently presented as late-onset [60.0 years (53.5\u201368.5), median (interquartile range)] pancerebellar syndrome, partly combined with afferent sensory deficits (55%) and dysautonomia (28%). Dysautonomia increased with duration while cognitive impairment remained infrequent, even in advanced stages. Cross-sectional and longitudinal assessments consistently indicated mild progression of ataxia [0.29 Scale for the Assessment and Rating of Ataxia (SARA) points\/year], not exceeding a moderate disease severity even in advanced stages (maximum SARA score: 18 points). Functional impairment increased relatively slowly (unilateral mobility aids after 8 years in 50% of patients). Corresponding to slow progression and low extra-cerebellar involvement, sNfL was not increased relative to controls. Concurrent second diseases (including progressive supranuclear palsy neuropathology) represented major individual aggravators of disease severity, constituting important caveats for planning future GAA-FGF14 trials. A treatment response to 4-AP with relevance for everyday living was reported by 86% of treated patients. A series of three prospective n-of-1 treatment experiences with on\/off design showed marked reduction in daily symptomatic time and symptom severity on 4-AP.<\/jats:p>\n               <jats:p>Our study characterizes the phenotypic profile, natural history progression, and 4-AP treatment response of GAA-FGF14 ataxia. It paves the way towards large-scale natural history studies and 4-AP treatment trials in this newly discovered, possibly most frequent, and treatable late-onset ataxia.<\/jats:p>","DOI":"10.1093\/brain\/awad157","type":"journal-article","created":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T09:23:54Z","timestamp":1683797034000},"page":"4144-4157","source":"Crossref","is-referenced-by-count":128,"title":["GAA-<i>FGF14<\/i> ataxia (SCA27B): phenotypic profile, natural history progression and 4-aminopyridine treatment response"],"prefix":"10.1093","volume":"146","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7250-8597","authenticated-orcid":false,"given":"Carlo","family":"Wilke","sequence":"first","affiliation":[{"name":"Division Translational Genomics of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research and Center of Neurology, University of T\u00fcbingen , 72076 T\u00fcbingen , Germany"},{"name":"German Center for Neurodegenerative Diseases (DZNE) , 72076 T\u00fcbingen , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Pellerin","sequence":"additional","affiliation":[{"name":"Department of Neurology and Neurosurgery, Montreal Neurological Hospital and Institute, McGill University , Montreal, Quebec H3A 1A1 , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Mengel","sequence":"additional","affiliation":[{"name":"Division Translational Genomics of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research and Center of Neurology, University of T\u00fcbingen , 72076 T\u00fcbingen , Germany"},{"name":"German Center for Neurodegenerative Diseases (DZNE) , 72076 T\u00fcbingen , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8165-5898","authenticated-orcid":false,"given":"Andreas","family":"Trasch\u00fctz","sequence":"additional","affiliation":[{"name":"Division Translational Genomics of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research and Center of Neurology, University of T\u00fcbingen , 72076 T\u00fcbingen , Germany"},{"name":"German Center for Neurodegenerative Diseases (DZNE) , 72076 T\u00fcbingen , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt C","family":"Danzi","sequence":"additional","affiliation":[{"name":"Dr. John T. Macdonald Foundation Department of Human Genetics and John P. Hussman Institute for Human Genomics, University of Miami Miller School of Medicine , Miami, FL 33136 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Jos\u00e9e","family":"Dicaire","sequence":"additional","affiliation":[{"name":"Department of Neurology and Neurosurgery, Montreal Neurological Hospital and Institute, McGill University , Montreal, Quebec H3A 1A1 , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Neumann","sequence":"additional","affiliation":[{"name":"German Center for Neurodegenerative Diseases (DZNE) , 72076 T\u00fcbingen , Germany"},{"name":"Department of Neuropathology, University of T\u00fcbingen , 72076 T\u00fcbingen , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"Lerche","sequence":"additional","affiliation":[{"name":"Department of Neurology and Epileptology, Hertie-Institute for Clinical Brain Research, University of T\u00fcbingen , 72076 T\u00fcbingen , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3205-4631","authenticated-orcid":false,"given":"Benjamin","family":"Bender","sequence":"additional","affiliation":[{"name":"Department of Diagnostic and Interventional Neuroradiology, University of T\u00fcbingen , 72016 T\u00fcbingen , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2866-7777","authenticated-orcid":false,"given":"Henry","family":"Houlden","sequence":"additional","affiliation":[{"name":"Department of Neuromuscular Disorders, UCL London, Institute of Neurology, University College London , London WC1N 3BG , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"RFC1 study group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Faber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Roxburgh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luiz","family":"Pedroso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula Camila","family":"Alvez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orlando","family":"Barsottini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Pane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Sacc\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Filla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo M","family":"Santorelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Ricca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5669-7415","authenticated-orcid":false,"given":"Stephan","family":"Z\u00fcchner","sequence":"additional","affiliation":[{"name":"Dr. John T. Macdonald Foundation Department of Human Genetics and John P. Hussman Institute for Human Genomics, University of Miami Miller School of Medicine , Miami, FL 33136 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludger","family":"Sch\u00f6ls","sequence":"additional","affiliation":[{"name":"German Center for Neurodegenerative Diseases (DZNE) , 72076 T\u00fcbingen , Germany"},{"name":"Department of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research and Center of Neurology, University of T\u00fcbingen , 72076 T\u00fcbingen , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1394-3561","authenticated-orcid":false,"given":"Bernard","family":"Brais","sequence":"additional","affiliation":[{"name":"Department of Neurology and Neurosurgery, Montreal Neurological Hospital and Institute, McGill University , Montreal, Quebec H3A 1A1 , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2280-7273","authenticated-orcid":false,"given":"Matthis","family":"Synofzik","sequence":"additional","affiliation":[{"name":"Division Translational Genomics of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research and Center of Neurology, University of T\u00fcbingen , 72076 T\u00fcbingen , Germany"},{"name":"German Center for Neurodegenerative Diseases (DZNE) , 72076 T\u00fcbingen , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,5,11]]},"reference":[{"key":"2023100302154494800_awad157-B1","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1212\/WNL.0000000000004311","article-title":"Clinical and genetic characteristics of sporadic adult-onset degenerative ataxia","volume":"89","author":"Giordano","year":"2017","journal-title":"Neurology"},{"key":"2023100302154494800_awad157-B2","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1212\/WNL.0000000000005055","article-title":"Comprehensive systematic review summary: Treatment of cerebellar motor dysfunction and ataxia: report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology","volume":"90","author":"Zesiewicz","year":"2018","journal-title":"Neurology"},{"key":"2023100302154494800_awad157-B3","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1056\/NEJMoa2207406","article-title":"Deep intronic FGF14 GAA repeat expansion in late-onset cerebellar ataxia","volume":"388","author":"Pellerin","year":"2023","journal-title":"N Engl J Med"},{"key":"2023100302154494800_awad157-B4","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ajhg.2022.11.015","article-title":"An intronic GAA repeat expansion in FGF14 causes the autosomal-dominant adult-onset ataxia SCA50\/ATX-FGF14","volume":"110","author":"Rafehi","year":"2023","journal-title":"Am J Hum Genet"},{"key":"2023100302154494800_awad157-B5","article-title":"Optimized testing strategy for the diagnosis of GAA-FGF14 ataxia","author":"Bonnet","journal-title":"medRxiv"},{"key":"2023100302154494800_awad157-B6","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1212\/01.wnl.0000219042.60538.92","article-title":"Scale for the assessment and rating of ataxia: Development of a new clinical scale","volume":"66","author":"Schmitz-Hubsch","year":"2006","journal-title":"Neurology"},{"key":"2023100302154494800_awad157-B7","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1007\/s12311-012-0421-3","article-title":"Inventory of Non-Ataxia Signs (INAS): validation of a new clinical assessment instrument","volume":"12","author":"Jacobi","year":"2013","journal-title":"Cerebellum"},{"key":"2023100302154494800_awad157-B8","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1212\/01.WNL.0000156802.15466.79","article-title":"Measuring Friedreich ataxia: interrater reliability of a neurologic rating scale","volume":"64","author":"Subramony","year":"2005","journal-title":"Neurology"},{"key":"2023100302154494800_awad157-B9","doi-asserted-by":"crossref","first-page":"e1369","DOI":"10.1212\/WNL.0000000000011528","article-title":"Natural history, phenotypic spectrum, and discriminative features of multisystemic RFC1 disease","volume":"96","author":"Traschutz","year":"2021","journal-title":"Neurology"},{"key":"2023100302154494800_awad157-B10","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.neuroimage.2017.02.016","article-title":"Evaluation of multimodal segmentation based on 3D T1-, T2- and FLAIR-weighted images\u2014The difficulty of choosing","volume":"170","author":"Lindig","year":"2018","journal-title":"Neuroimage"},{"key":"2023100302154494800_awad157-B11","doi-asserted-by":"crossref","first-page":"e1985","DOI":"10.1212\/WNL.0000000000200257","article-title":"Levels of neurofilament light at the preataxic and ataxic stages of spinocerebellar ataxia type 1","volume":"98","author":"Wilke","year":"2022","journal-title":"Neurology"},{"key":"2023100302154494800_awad157-B12","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201911803","article-title":"Neurofilaments in spinocerebellar ataxia type 3: blood biomarkers at the preataxic and ataxic stage in humans and mice","volume":"12","author":"Wilke","year":"2020","journal-title":"EMBO Mol Med"},{"key":"2023100302154494800_awad157-B13","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s00401-008-0477-9","article-title":"Phosphorylation of S409\/410 of TDP-43 is a consistent feature in all sporadic and familial forms of TDP-43 proteinopathies","volume":"117","author":"Neumann","year":"2009","journal-title":"Acta Neuropathol"},{"key":"2023100302154494800_awad157-B14","doi-asserted-by":"crossref","first-page":"e174","DOI":"10.1212\/WNL.0000000000012998","article-title":"N-of-1 trials in neurology: a systematic review","volume":"98","author":"Stunnenberg","year":"2022","journal-title":"Neurology"},{"key":"2023100302154494800_awad157-B15","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"key":"2023100302154494800_awad157-B16","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1089\/nat.2021.0039","article-title":"Preparing n-of-1 antisense oligonucleotide treatments for rare neurological diseases in Europe: genetic, regulatory, and ethical perspectives","volume":"32","author":"Synofzik","year":"2022","journal-title":"Nucleic Acid Ther"},{"key":"2023100302154494800_awad157-B17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v067.i01","article-title":"Fitting linear mixed-effects models using lme4","volume":"67","author":"Bates","year":"2015","journal-title":"J Stat Softw."},{"key":"2023100302154494800_awad157-B18","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/S1474-4422(15)00202-1","article-title":"Long-term disease progression in spinocerebellar ataxia types 1, 2, 3, and 6: a longitudinal cohort study","volume":"14","author":"Jacobi","year":"2015","journal-title":"Lancet Neurol"},{"key":"2023100302154494800_awad157-B19","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1212\/01.wnl.0000324625.00404.15","article-title":"Second consensus statement on the diagnosis of multiple system atrophy","volume":"71","author":"Gilman","year":"2008","journal-title":"Neurology"},{"key":"2023100302154494800_awad157-B20","doi-asserted-by":"crossref","first-page":"6354","DOI":"10.1007\/s00415-022-11253-1","article-title":"Unravelling the etiology of sporadic late-onset cerebellar ataxia in a cohort of 205 patients: a prospective study","volume":"269","author":"Bogdan","year":"2022","journal-title":"J Neurol"},{"key":"2023100302154494800_awad157-B21","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1007\/s00415-018-8893-9","article-title":"Serum neurofilament light is increased in multiple system atrophy of cerebellar type and in repeat-expansion spinocerebellar ataxias: a pilot study","volume":"265","author":"Wilke","year":"2018","journal-title":"J Neurol"},{"key":"2023100302154494800_awad157-B22","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/mds.28783","article-title":"Blood neurofilament light chain in genetic ataxia: a meta-analysis","volume":"37","author":"Peng","year":"2022","journal-title":"Mov Disord"},{"key":"2023100302154494800_awad157-B23","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1002\/mds.29032","article-title":"Paving the way toward meaningful trials in ataxias: an ataxia global initiative perspective","volume":"37","author":"Klockgether","year":"2022","journal-title":"Mov Disord"},{"issue":"Pt 1","key":"2023100302154494800_awad157-B24","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1113\/jphysiol.2005.097220","article-title":"Fibroblast growth factor 14 is an intracellular modulator of voltage-gated sodium channels","volume":"569","author":"Lou","year":"2005","journal-title":"J Physiol"},{"key":"2023100302154494800_awad157-B25","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.mcn.2009.05.007","article-title":"FGF14 N-terminal splice variants differentially modulate Nav1.2 and Nav1.6-encoded sodium channels","volume":"42","author":"Laezza","year":"2009","journal-title":"Mol Cell Neurosci"},{"key":"2023100302154494800_awad157-B26","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.nbd.2008.09.019","article-title":"FGF14 Regulates the intrinsic excitability of cerebellar Purkinje neurons","volume":"33","author":"Shakkottai","year":"2009","journal-title":"Neurobiol Dis"},{"key":"2023100302154494800_awad157-B27","doi-asserted-by":"crossref","first-page":"29489","DOI":"10.1038\/srep29489","article-title":"4-aminopyridine reverses ataxia and cerebellar firing deficiency in a mouse model of spinocerebellar ataxia type 6","volume":"6","author":"Jayabal","year":"2016","journal-title":"Sci Rep."},{"key":"2023100302154494800_awad157-B28","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1007\/s00415-013-7029-5","article-title":"Experience in a short-term trial with 4-aminopyridine in cerebellar ataxia","volume":"260","author":"Giordano","year":"2013","journal-title":"J Neurol"},{"key":"2023100302154494800_awad157-B29","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2174\/1570159X16666180905093535","article-title":"Aminopyridines and acetyl-DL-leucine: new therapies in cerebellar disorders","volume":"17","author":"Kalla","year":"2019","journal-title":"Curr Neuropharmacol"},{"key":"2023100302154494800_awad157-B30","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s12311-015-0733-1","article-title":"Update on the pharmacotherapy of cerebellar ataxia and nystagmus","volume":"15","author":"Feil","year":"2016","journal-title":"Cerebellum"}],"container-title":["Brain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/brain\/advance-article-pdf\/doi\/10.1093\/brain\/awad157\/50633126\/awad157.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/brain\/article-pdf\/146\/10\/4144\/51824257\/awad157.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/brain\/article-pdf\/146\/10\/4144\/51824257\/awad157.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T02:25:18Z","timestamp":1696299918000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/brain\/article\/146\/10\/4144\/7159816"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,11]]},"references-count":30,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,5,11]]},"published-print":{"date-parts":[[2023,10,3]]}},"URL":"https:\/\/doi.org\/10.1093\/brain\/awad157","relation":{},"ISSN":["0006-8950","1460-2156"],"issn-type":[{"value":"0006-8950","type":"print"},{"value":"1460-2156","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,10]]},"published":{"date-parts":[[2023,5,11]]}}}